Aldeyra Therapeutics Inc (ALDX)

[Rayn_Makr]

RASP-INHIBITION IN SYSTEMIC DISEASES

ADX-629 became a topic in the recent conference call so I did a revisit of that therapeutic. Glad I did since ADX-629 offers an impressive opportunity to further RASP inhibition. Several nuggets to pass along from a quick review of ADX-629:

The clinical trial NCT04847544 for Treatment of COVID-19 was initiated in April. It is recruiting N=30 and estimated completion this year.

https://clinicaltrials.gov/ct2/show/NCT04847544?term=aldeyra&recrs=abdf&draw=2&rank=1

Secondly, the phase 1 results showed target engagement "Also Improved Lipid Profiles". Lipid therapeutics have a large market, i.e., cardiovascular disease. Look at slide #17.

https://ir.aldeyra.com/static-files/33742ce3-ebdc-4569-9f65-b5b7bd8c73eb

The asthma trial is also on the trial list.

https://clinicaltrials.gov/ct2/results?term=aldeyra&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply%5D

Six ongoing clinical trials explains the recent raise in capital and great timing on that. Kudos to management!